SLC5A2 and osteosarcoma: To determine the specific mechanism by which SGLT2 inhibitor treatment promoted the infiltration of immune cells in osteosarcoma, we performed KEGG signaling pathway enrichment analysis based on RNA sequence data, showing that the cytosolic DNA-sensing pathway was significantly enriched, and the expression of STING was significantly upregulated in the SGLT2 inhibitor (Canagliflozin, 1.0 uM [19, 20]) treatment group (Fig. 4a and Supplementary Table 3).